Location History:
- Steinhausen, CH (2016 - 2022)
- Hünenberg, CH (2022)
Company Filing History:
4 out of 5 
4 out of 9 
1 out of 5 Years Active: 2016-2022
Title: The Innovations of Titus Kretzschmar
Introduction
Titus Kretzschmar is a distinguished inventor based in Steinhausen, Switzerland, known for his significant contributions to the field of biomedicine. With a total of nine patents under his name, Kretzschmar has made remarkable advancements that impact the treatment of various diseases, particularly in the realm of cancer and inflammatory conditions.
Latest Patents
Among his latest innovations are two notable patents focusing on antibody fragments. The first invention relates to anti-PD-L1 binding members, specifically monovalent, high potency PD-L1-binding antibody fragments that exhibit high stability and solubility. These binding members have promising applications in cancer therapies and inflammatory disease treatment, as well as in diagnostic methods.
The second patent details anti-IL-1 beta antibodies, particularly monovalent high potency IL-1 beta-binding antibody fragments that demonstrate robust stability. This invention opens avenues for novel treatments of inflammatory diseases and potential diagnostic uses, further underscoring Kretzschmar's commitment to improving healthcare with biotherapeutic solutions. Both patents also include related nucleic acids, vectors, cells, and compositions, showcasing the comprehensive nature of his research.
Career Highlights
Titus Kretzschmar has worked with esteemed organizations such as Cell Medica Switzerland AG and Cell Medica Limited, where he has collaborated on various innovative projects that advance medical therapies. His experience in these companies has positioned him as a key figure in the field of monoclonal antibody development.
Collaborations
Throughout his career, Kretzschmar has had the pleasure of working alongside talented individuals, including Abdijapar Shamshiev and Stefanie Grabulovski. These collaborations have enhanced the scope of his research and contributed to the successful outcomes of his inventions.
Conclusion
Titus Kretzschmar’s dedication to innovation in biomedicine is evident through his extensive patent portfolio and collaborations with leading companies and experts in the field. His work continues to pave the way for evolving treatments that have the potential to significantly improve patient outcomes and push the boundaries of medical science.